NCX-4016 NicOx.
NCX-4016 is a nitric oxide-aspirin conjugate non-steroidal anti-inflammatory drug that is under investigation by NicOx for the potential treatment of cardiovascular disorders and colon cancer. In April 2002, a phase II clinical trial was initiated in symptomatic peripheral arterial disease, and in March 2003, the University of Michigan was awarded a grant by the NIH to conduct a phase II trial in individuals at risk of colon cancer.
Neurological Section, SMDN-Center for Cardiovascular Medicine and Cerebrovascular Disease Prevention, 41 Via Trento, I-67039-Sulmona, AQ, Italy. mariodinapoli@katamail.com
Mario
M
Di Napoli
Francesca
F
Papa
D000818:Animals; D001241:Aspirin / Q000008:administration & dosage / Q000031:analogs & derivatives / Q000737:chemistry / Q000627:therapeutic use*; D002318:Cardiovascular Diseases / Q000188:drug therapy / Q000201:enzymology / Q000517:prevention & control*; D017321:Clinical Trials, Phase I as Topic; D017322:Clinical Trials, Phase II as Topic; D003110:Colonic Neoplasms / Q000201:enzymology / Q000517:prevention & control*; D016861:Cyclooxygenase Inhibitors / Q000008:administration & dosage / Q000737:chemistry / Q000627:therapeutic use*; D006801:Humans; D015394:Molecular Structure; D009569:Nitric Oxide / Q000096:biosynthesis; D010975:Platelet Aggregation Inhibitors / Q000008:administration & dosage / Q000737:chemistry / Q000627:therapeutic use*; D016032:Randomized Controlled Trials as Topic; D013329:Structure-Activity Relationship
D016861:Cyclooxygenase Inhibitors; D010975:Platelet Aggregation Inhibitors; D009569:Nitric Oxide; C102148:nitroaspirin; D001241:Aspirin